Dianthus Therapeutics, INC. /De/ (DNTH) — 10-Q Filings

All 10-Q filings from Dianthus Therapeutics, INC. /De/. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Dianthus's Net Loss Widens 73% Amid Soaring R&D, Cash Reserves Up — Nov 5, 2025 Risk: high
Dianthus Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $97.905 million, up from $56.529
Dianthus's Net Loss Widens to $45.2M Amid Rising R&D Costs — Aug 7, 2025 Risk: high
Dianthus Therapeutics, Inc. reported no revenue for the six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for the
Dianthus Therapeutics Q1 2025 Update — May 12, 2025 Risk: low
Dianthus Therapeutics, Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's former name was Magenta Therapeutics, In
Dianthus Therapeutics Q3 2024 Update — Nov 7, 2024 Risk: medium
Dianthus Therapeutics, Inc. reported its third quarter 2024 results, ending September 30, 2024. The company's financial statements show changes in various equit
Dianthus Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
Dianthus Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business
Dianthus Therapeutics Files 10-Q for Q1 2024 — May 9, 2024 Risk: medium
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Dianthus Therapeutics, Inc. filed its 10-Q for the period e

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX